The pathophysiology and management of diuretic resistance in patients with heart failure

References

• Hoorn EJ, Ellison DH. Diuretic resistance. Am J Kidney Dis. 2017;69(1):136–142.
   PubMed Web of Science ®Google Scholar
• Shah N, Madanieh R, Alkan M. A perspective on diuretic resistance in chronic congestive heart failure. Ther Adv Cardiovasc Dis. 2017;11(10):271–278.
   PubMedGoogle Scholar
• Gupta R, Testani J, Collins S. Diuretic resistance in heart failure. Curr Heart Fail Rep. 2019;16(2):57–66.
   PubMedGoogle Scholar
• Wilcox CS, Testani JM, Pitt B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension. 2020;76(4):1045–1054.
   Web of Science ®Google Scholar
• Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29(3):367–372.
   PubMed Web of Science ®Google Scholar
• Taylor SH. Diuretic therapy in congestive heart failure. Cardiol Rev. 2000;8(2):104–114.
   PubMedGoogle Scholar
• Kammer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106(1):90–96.
   PubMed Web of Science ®Google Scholar
• Smith GL, Lichtman JH, Bracken MB. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987–1996.
   PubMed Web of Science ®Google Scholar
• Ezekowitz J, McAlister FA, Humphries KH. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44(8):1587–1592.
   PubMed Web of Science ®Google Scholar
• Hillege HL, Girbes AR, de Kam PJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102(2):203–210.
   PubMed Web of Science ®Google Scholar
• Adams KF, Fonanow GC, Emerman CL. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J. 2005;1492:209–216.
   PubMed Web of Science ®Google Scholar
• Heywood JT, Fonarow GC, Costanzo MR. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422–430.
   PubMed Web of Science ®Google Scholar
• Ter Maaten JM, Valente MA, Damman K. Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 2015;12(3):184–192 .
   PubMed Web of Science ®Google Scholar
• Testani JM, Hanberg JS, Cheng S. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail. 2016;9(1):e002370.
   PubMed Web of Science ®Google Scholar
• Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577–585.
   PubMed Web of Science ®Google Scholar
• Weber KT. Aldosteronism in congestive heart failure. N ENGL J Med. 2001;345(23):1689–1697.
   PubMed Web of Science ®Google Scholar
• Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med. 1991;114(10):886–894.
   PubMed Web of Science ®Google Scholar
• Vargo DL, Kramer WG, Black PK. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57(6):601–609.
   PubMed Web of Science ®Google Scholar
• DC B, Day B, Burdette A. Bumetanide and furosemide in heart failure. Kidney Int. 1984;26(2):183–189.
   PubMed Web of Science ®Google Scholar
• Uwai Y, Satto H, Hashimoto Y. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000;295(1):261–265.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Solomon SD, Gerstein HC. Albuminuria in chronic heart failure: prevalence and prognostic significance. Lancet. 2009;374(9689):543–550.
   PubMed Web of Science ®Google Scholar
• Hesse B, Parving HH, Lund-Jacobsen H. Trascappillary escape rate of albumin and right atrial pressure in chronic congestive heart failure before and after treatment. Circ Res. 1976;39(3):358–362.
   PubMed Web of Science ®Google Scholar
• Wilcox C, Mitch WE, Kelly RA. Response of the kidney to furosemide, I. Effects of salt intake and renal compensation. J Lab Clin Med. 1983;102(3):450–458.
   PubMed Web of Science ®Google Scholar
• Brater DC. An update in diuretic therapy: clinical pharmacology. Semin Nephrol. 2011;31(6):483–4994.
   PubMed Web of Science ®Google Scholar
• Huang X, Dorhout Mees E, Vos P. Everything we always wanted to know about and furosemide but we were afraid to ask. Am J Physiol Renal Physiol. 2016;310(10):958-971.
   Web of Science ®Google Scholar
• Goldsmith SR. The role of vasopressin in congestive heart failure. Cleve Clin J Med. 2006;73(Suppl 3):S19–S23.
   PubMed Web of Science ®Google Scholar
• Lanfear DE, Sabbath HN, Goldsmith SR. EVEREST trial investigators. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2013;6(1):47–52.
   PubMed Web of Science ®Google Scholar
• Kidada S, Kikuchi S, Sonoda H. Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure. J Int Med Res. 2016;44(6):1430–1442.
   PubMed Web of Science ®Google Scholar
• Hanberg JS, Rao V, Ter Maaten JM. Hypochloremia and diuretic resistance in heart failure: metabolic insights. Circ Heart Fail. 2016;9(8):10.1161.
   Web of Science ®Google Scholar
• Hropot M, Klaus E, Unwin R. Diminished diuretic and natriuretic response to furosemide in potassium-depleted rats. Ren Physiol Biochem. 1994;17(1):10–20.
   PubMedGoogle Scholar
• Kuchar DL, O’Rourke MP. High-dose furosemide in the treatment of refractory cardiac failure. Eur Heart J. 1985;6(11):954–958.
   PubMed Web of Science ®Google Scholar
• Gerlag PGG, van Meijel JJM. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med. 1988;148(2):286–291.
   PubMedGoogle Scholar
• Gamba G, Friedman PA. Thick ascending limb: Na+; K+; 2Cl− co-transporter, NKCC2, and the calcium-sensing receptor, CaSR. Pfugers Arch. 2009;458(1):61–76.
   PubMed Web of Science ®Google Scholar
• Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line?. Ann Pharmacother. ;2009(43): 1836- 1847.
   Google Scholar
• Casu G, Merella P. Diuretic therapy in heart failure-current approaches. Eur Cardiol. 2015;10(1):42–47.
   PubMed Web of Science ®Google Scholar
• Raftery EB. Hemodynamic effects of diuretics in heart failure. Br Heart J. 1994;72(Suppl 2 Suppl):S44- S47.
   PubMedGoogle Scholar
• Chrysant SG. Effects of high salt intake on blood pressure and cardiovascular disease: the role of COX inhibitors. Clin Cardiol. 2016;39(4):240–242.
   PubMed Web of Science ®Google Scholar
• Jessup M, Abraham WT, Casey DE. ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American college of cardiology foundation/American heart association task force on practice guidelines: developed in collaboration with the international society for heart and lung transplantation. Circulation. 2009; 119: 1977–2016.
   PubMed Web of Science ®Google Scholar
• Hasselblad V, Stough WG, Shah MR. Relation between dose of loop diuretics and outcomes in heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9(10):1064–1069.
   PubMed Web of Science ®Google Scholar
• Testani JM, Cappola TP, Brensiger CM. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol. 2011;58(4):375–382.
   PubMed Web of Science ®Google Scholar
• Butler J, Forman DE, Abraham WT. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147(2):331–338.
   PubMed Web of Science ®Google Scholar
• Felker CM, Lee KL, Bull DA. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805.
   PubMed Web of Science ®Google Scholar
• Allen LA, Turer AT, DeWald T. Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol. 2010;105(12):1794–1797.
   PubMed Web of Science ®Google Scholar
• Thomson MR, Nappi JM, Dunn SP. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail. 2010;16(3):188–193.
   PubMed Web of Science ®Google Scholar
• Palzuzuoli A, Pellegrini M, Ruocco G. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Crit Care. 2014;18(3):R134.
   PubMed Web of Science ®Google Scholar
• Amer M, Adomaiyte J, Qayyum R. Continuous infusion versus intermittent bolus furosemide in ADHF: an updated meta-analysis of randomized trials. J Hosp Med. 2012;7(3):270–275.
   PubMed Web of Science ®Google Scholar
• Wu MY, Chang NC, Su CL. Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials. J Crit Care. 2014;29(1):2–9.
   PubMed Web of Science ®Google Scholar
• Neuberg GW, Miller AB, O’Connor CM. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144(1):31–38.
   PubMed Web of Science ®Google Scholar
• Ramsay F, Crawford RJ, Allman S. An open comparative study of two diuretic combinations, furosemide/amiloride (Frumil) and bumetanide/potassium chloride (Burinex K), in the treatment of congestive cardiac failure in hospital out-patients. Curr Med Res Opin. 1988;10(10):682–689.
   PubMed Web of Science ®Google Scholar
• Murray MD, Deer MM, Ferguson JA. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111(7):513–520.
   PubMed Web of Science ®Google Scholar
• Cosin J, Diez J. on behalf of the TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507–513.
   PubMed Web of Science ®Google Scholar
• Muller K, Gamba G, Jaquet F. Torasemide vs furosemide in primary care patients with chronic heart failure NYHA II to IV- efficacy and quality of life. Eur J Heart Fail. 2003;5(6):793–801.
   PubMed Web of Science ®Google Scholar
• Jentzer JC, DeWald TA, Hernabdez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527–1534.
   PubMed Web of Science ®Google Scholar
• Kunau RT Jr, Weller DR, Webb HL. Clarification of the site of action of chlorothiazide in the rat nephron. J Clin Invest. 1975;56(2):401–407.
   PubMed Web of Science ®Google Scholar
• Ng TM, Konopka E, Hyderi AF. Comparison of bumetanide and metolazone –based diuretic regimens to furosemide in acute heart failure. J Cardiovasc Pharmacol Ther. 2013;18(4):345–353.
   PubMed Web of Science ®Google Scholar
• Tilstone WJ, Dargie H, Dargie EN. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther. 1974;16(2):322–329.
   PubMed Web of Science ®Google Scholar
• Sica DA. Metolazone and its role in edema management. Congest Heart Fail. 2003;9(2):100–105.
   PubMedGoogle Scholar
• Kiyingi A. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet. 1990;335(8680):29–31.
   PubMed Web of Science ®Google Scholar
• Olesen KH, Sigmund B. The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide during long-term treatment with furosemide and spironolactone. Permutation trial tests in patients with congestive heart failure. Acta Med Scand. 2009;190(1–6):233–240.
   Google Scholar
• Channer KS, McLean KA, Lawson-Matthews P. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994;71(2):146–150.
   PubMedGoogle Scholar
• US National Library of Medicine, Clinicaltials.gov [0nlin]. [Cited 2021 Feb 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT01973335 . 2014.
   Google Scholar
• US National Library of Medicine, Clinicaltrials.gov[online]. [Cited 2021 Feb 12]. Available from: https://clinicaltrials.gov[online], https://clinicaltrials.gov/ct2/show/NCT01647932, 2014.
   Google Scholar
• Imiela T, Budaj A. Acetazolamide as add-on therapy in exacerbations of chronic heart failure: a pilot study. Clin Drug Investig. 2017;37(12):1175–1181.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme W. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–717.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Menard J, Fay R. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. J Am Coll Cardiol. 2011;58(19):1958–1966.
   PubMed Web of Science ®Google Scholar
• Pitt B. Aldosterone blockade in patients with chronic heart failure. Cardiol Clin. 2008;26(1):15–21.
   PubMed Web of Science ®Google Scholar
• Aronson D, Burger AJ. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol. 2003;91(2):245–248.
   PubMed Web of Science ®Google Scholar
• Masoumi A, Ortiz F, Radhakrshnan J. Mineralocorticoid receptor antagonists as diuretics: can congestive heart failure learn from liver failure?. Heart Fail Rev. 2014;20(3):283–290.
   Web of Science ®Google Scholar
• Wilcox CS, Shen W, Boulton DW. Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc. 2018;7(4):e007046.
   PubMed Web of Science ®Google Scholar
• Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension. 2020;75(4):894–901.
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs. Drugs Today. 2017;53(3):191–202.
   PubMed Web of Science ®Google Scholar
• Sternlicht H, Bakris GL. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis. Curr Hypertens Rep. 2019;21(2):12.
   PubMed Web of Science ®Google Scholar
• Thomson SC, Rieg T, Miracle C. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302(1):R75- R83.
   PubMed Web of Science ®Google Scholar
• Beloto-Silva O, Machado UP, Oliveira-Souza M. Glucose-induced regulation of NHEs activity and SGLTs expression involves the PKA signaling pathway. J Membr Biol. 2011;239(3):157–165.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Basuray A, Dolansky M, Josephon R. Dietary sodium adherence is poor in chronic heart failure patients. J Card Fail. 2015;21(4):323–329.
   PubMed Web of Science ®Google Scholar
• De Bruyne LKM. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med. 2003;79(931):268–271.
   Google Scholar
• Elison DH, Velazquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest. 1989;83(1):113–126.
   PubMed Web of Science ®Google Scholar
• Felker GM, Ellison DH, Mullens W. Diuretic therapy for patients with heart failure. JACC State-of-the-art review. J Am Coll Cardiol. 2020;75:1179–1195.
   Google Scholar
• Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010;121(23):2592–2600.
   PubMed Web of Science ®Google Scholar
• Nohria A, Hasselblad V, Stebbins A. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51(13):1268–1274.
   PubMed Web of Science ®Google Scholar
• Testani JM, Brisco MA, Turner JM. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7(2):261–270.
   PubMed Web of Science ®Google Scholar
• Ter Maaten JM, Dunning AM, Valente MA. Diuretic response in acute heart failure: an analysis of ASCEND-HF. Am Heart J. 2015;170(2):313–321.
   PubMed Web of Science ®Google Scholar
• Rao VS, Planavsky N, Hanberg JS. Compensatory distal reabsorption drives resistance in human heart failure. J Am Soc Nephrol. 2017;28(11):3414–3424.
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Eshalier R, Duarte K. Reduced diuretic dose in patients treated with eplerenone. Data from the EPHESUS trial. Circ Heart Fail. 2020;13(5):e006597.
   PubMed Web of Science ®Google Scholar
• Mullens W, Verbrugge FH, Nijst P. Rationale and design of the ADVOR (Acetazolamide in decompensated heart failure with volume overload) trial. Eur J Heart Fail. 2018;20(11):1591–1600.
   PubMed Web of Science ®Google Scholar
• Griffin M, Rao VS, Ivey-Miranda J. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142(11):1028–1039.
   PubMed Web of Science ®Google Scholar
• Wan SH, Stevens SR, Borlaug BA. Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF trial (Renal optimization strategies evaluation in acute heart failure). Circ Heart Fail. 2016;9(8):e002593.
   PubMed Web of Science ®Google Scholar
• Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 2017: 69: 1399–1406
   Google Scholar